國家衛生研究院 NHRI:Item 3990099045/12704
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 910955      線上人數 : 941
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12704


    題名: Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
    作者: Chiang, NJ;Chen, MH;Yang, SH;Hsu, C;Yen, CJ;Tsou, HH;Su, YY;Chen, JS;Shan, YS;Chen, LT
    貢獻者: National Institute of Cancer Research;Institute of Population Health Sciences
    摘要: BACKGROUND & AIMS: Gemcitabine plus cisplatin (GC) remains the standard, frontline therapy for advanced biliary tract cancer (ABTC). The JCOG1113 study suggested that the median overall survival and incidence of significant neutropenia after gemcitabine plus S-1 (GS) and GC treatments were comparable. This study evaluates the efficacy and safety of the modified GS regimen. METHODS: The eligible patients with chemonaive, measurable ABTC received 800 mg/m(2) of gemcitabine on day 1 and 80 mg/m(2) /day of S-1 (80/100/120 mg for patients with body surface <1.25/ ≥1.25 and <1.5/ ≥1.5m(2) , respectively). The primary endpoint (PE) was the 12-week disease control rate (12-week DCR: objective response and stable disease ≥12 weeks). Per the p0=40% and p1=60% (a/b=0.05/0.2) assumption, Simon's optimal 2-stage design indicated 12-week DCR in ≥24 of 46 evaluable patients for significant activity. Tumour responses were assessed every 6 weeks. RESULTS: Fifty-one patients were enrolled and most of them had intrahepatic cholangiocarcinoma (64.7%), metastatic disease (84.3%) and disease-related symptoms (82.4%). On intention-to-treat analysis, 11 (21.6%) patients showed partial response, whereas 21 (41.2%) showed stable disease ≥12 weeks. The progression-free and overall survival of 5.4 months (95% confidence interval [CI]: 3.5-7.0), and 12.7 months (95% CI: 6.1-15.6), respectively. The study met its PE with a 12-week DCR of 69.6% in 46 evaluable patients. Grade 3/4 treatment-related adverse events occurred in <6% of patients. The mean dose intensities of S-1 and gemcitabine were 87.1% and 92.5%, respectively. CONCLUSIONS: Modified GS showed moderate efficacy with a favourable safety profile in ABTC patients, thus mandating further assessment.
    日期: 2020-10
    關聯: Liver International. 2020 Oct;40(10):2535-2543.
    Link to: http://dx.doi.org/10.1111/liv.14538
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1478-3223&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000539016900001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85086172033
    顯示於類別:[陳立宗] 期刊論文
    [姜乃榕] 期刊論文
    [鄒小蕙] 期刊論文
    [蘇勇曄] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB32463975.pdf13231KbAdobe PDF375檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋